Why the study?
Cardiovascular disease is the leading cause of competitive mortality in female breast cancer, but the efficacy, safety, and evidence quality of aerobic exercise on cardiovascular risk factors required evaluation.
Does aerobic exercise reduce cardiovascular disease events in female breast cancer patients?
Does aerobic exercise reduce cardiovascular disease events in female breast cancer patients?
Aerobic exercise significantly reduces the risk of cardiovascular and coronary artery disease events in female breast cancer patients, while also improving surrogate markers like VO2 max and LDL-C.
Aerobic exercise cuts CVD events ~29% in breast cancer patients; extends evidence supporting its role in cardio-oncology care.
Background Cardiovascular disease (CVD) has become the leading cause of competitive mortality in female breast cancer (BC). Regular aerobic exercise (AE) has been widely accepted as an effective intervention to reduce cardiovascular risk in a variety of different clinical conditions. This study is aimed at evaluating the efficacy and safety of AE on cardiovascular risk factors in female BC and assessing the quality of the synthesized evidence. Methods We searched five English databases (Cochrane Library, PubMed, Embase, Scopus, and Web of Science) from inception to January 2023. Randomized controlled trials (RCTs) and cohort trials studying the effects of AE were included. We used Stata 16 for data synthesis, Risk of Bias 2, and the Newcastle-Ottawa Scale for methodological quality evaluation and assessed the certainty of the synthesized evidence in the Grading of Recommendations, Assessment, Development and Evaluations (GRADE) approach. Results Forty RCTs and 6 cohort trials involving 59,050 BC patients showed AE reduced the incidence of CVD events by 29.4% [RR = 0.706, 95% CI (0.659, 0.757), low certainty] and coronary artery disease events by 36% (risk ratio [RR]: 0.64, 95% confidence interval [CI] [0.561, 0.729]; risk difference [RD] = 23.2%, 95% CI [17.6%, 29.6%], low certainty]. AE improved LVEF, and reduced weight and hip circumference. The subgroup analysis results showed that nonlinear AE increased VO 2 max by 5.354 ml·kg·min − 1 [MD 5.354, 95% CI (2.645, 8.062), very low certainty] and reduced fat mass by 4.256 kg [MD 4.256, 95% CI (-3.839, -0.094), very low certainty]. While linear AE reduced low-density lipoprotein cholesterol (LDL-C) by 8.534 mg/dL [MD -8.534, 95% CI (-15.511, -1.557), low certainty]. The sensitivity analysis results showed that each trial did not affect the impact index of the highly heterogeneous outcomes. Conclusions Our study indicates that AE has a positive effect in reducing cardiovascular risk factors. The principles of AE especially nonlinear design deserve more attention in the future. This will provide new ideas to reduce CVD events and improve the quality of life in female BC patients. However, further research on AE in female BC should take into account long-term and well-designed administration to draw definitive conclusions.
No takes yet. Share an insight, caveat, or question.
Jiao et al. (2023) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: